Skip to content
EmergingResearch compoundLimited evidence

Dihexa

Experimental nootropic that improved connections between nerve cells and memory in animals; not studied in humans.

NootropicPeptideMemoryNeuroprotectionBDNFBDNFGlutamate
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassPeptide · Memory · Neuroprotection · BDNF
Primary targetHGF / c-Met superagonist
Targets3 receptor targets
EvidenceLimited evidence
Affected systemsBDNFGlutamate

Contents

DETAILED OVERVIEW

What is Dihexa?

Dihexa is an experimental research compound: a derivative of the peptide angiotensin IV (a short protein chain) developed in a university lab and more resistant to breakdown. It was developed to promote the growth of connections (synapses) between nerve cells in the brain. It is not an approved medicine anywhere and is sold as a research chemical.

In animal studies, the density of connection points between nerve cells in the hippocampus, a brain area important for memory, increased nearly threefold, and spatial and long-term memory improved. The exact mechanism is disputed: the explanation originally proposed was later reviewed. It has not been studied in humans: there are only early, mostly laboratory and animal data, and no human safety data. Because the suggested signaling pathway also stimulates cell growth and the formation of new blood vessels, it could in theory carry a tumor risk; its safety in pregnancy and breastfeeding has not been established.

Mechanism

HGF/c-Met receptor agonist

Half-life

No human data

Legal status

Investigational, not approved

Receptor profile

  • HGF / c-Met receptorStrong
  • PI3K/Akt pathwayStrong
  • MAPK/ERK pathwayStrong

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • No published human safety data; the side-effect profile in humans is essentially unknown, only preclinical and anecdotal reports exist.
  • Theoretical tumor and angiogenesis risk: HGF/c-Met pathway activation is a known cell-proliferation and angiogenic signaling route, its long-term human effect is uncharacterized.
  • Appetite suppression according to some user reports.
  • Overdose risk from extreme potency: estimated potency is many times that of BDNF, so even a small dosing error may trigger a disproportionate biological effect.
  • Unknown long-term safety; the consequences of chronic synaptogenic signaling in humans are not known.

Contraindications · 5

  • Active or prior malignancy, or elevated cancer risk: avoid due to the proliferative and angiogenic action of the c-Met/HGF pathway.
  • Pregnancy and breastfeeding: no safety data, the effect of growth-factor signaling on fetus/infant is unknown, avoid.
  • No human approval: not an approved drug anywhere, purely an experimental research chemical; use without medical supervision is not advised.
  • Undefined drug interactions: human half-life and metabolism are unknown, so the risk of co-administration with other agents cannot be estimated.
  • Diabetic retinopathy or other conditions involving pathological neovascularization: extra caution due to the theoretical angiogenic effect.

Related Nootropics

Same therapeutic category

FAQ

FAQ

Dihexa is an experimental research compound developed in a university lab with the goal of promoting growth of connections between brain cells (synapses), by mimicking a natural growth-factor signaling pathway. The available evidence is purely preclinical, meaning animal-study level, there is no human research or proven benefit, so it cannot be considered an established or safely used substance.

Telegram

Have a question about Dihexa?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC26H41N5O5
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.